tiprankstipranks
Trending News
More News >
Beyond Air Inc (XAIR)
NASDAQ:XAIR

Beyond Air (XAIR) AI Stock Analysis

Compare
585 Followers

Top Page

XA

Beyond Air

(NASDAQ:XAIR)

Rating:43Neutral
Price Target:
$0.00
▼(-100.00%Downside)
The overall stock score reflects substantial financial risks due to persistent losses and negative cash flows, which are partially mitigated by positive revenue growth and strategic corporate actions. Despite technical and valuation challenges, the company's strategic initiatives and international expansion offer some potential for future improvement.
Positive Factors
Financial Performance
3Q25 LungFit PH revenue of $1.1M was above our estimate of $0.88M.
Market Expansion
The company secured new distribution partnerships in Europe and the Middle East, reaching a total of more than 25 countries covered.
Product Innovation
Beyond Air's systems deliver unlimited and on-demand nitric oxide from ambient air via ionization with its patented Plasma Pulse Technology, offering a simpler solution compared to competitor systems that use cumbersome and risky compressed gas cylinders.
Negative Factors
Cash Management
Cash burn is anticipated to continue trending lower, but not to the same extent as F3Q due to planned submission activities.
Revenue Challenges
Beyond Air faced setbacks and challenges in its initial commercial efforts, which limited its ability to achieve substantial revenue due to delays and disruptions during the COVID-19 pandemic and a failed agreement with a partner.

Beyond Air (XAIR) vs. SPDR S&P 500 ETF (SPY)

Beyond Air Business Overview & Revenue Model

Company DescriptionBeyond Air, Inc. (XAIR) is a medical device and biopharmaceutical company focused on developing and commercializing innovative products for patients with respiratory conditions. The company's core technology is centered around the LungFit™ platform, which is designed to deliver nitric oxide for therapeutic use in various respiratory diseases. Beyond Air operates within the healthcare sector, specifically targeting the medical devices and respiratory therapy markets.
How the Company Makes MoneyBeyond Air generates revenue primarily through the commercialization of its LungFit™ platform, which delivers nitric oxide for treating respiratory conditions such as bronchiolitis and chronic obstructive pulmonary disease (COPD). The company aims to monetize its technology by obtaining regulatory approvals, launching its devices in key markets, and establishing partnerships with healthcare providers and distributors. Beyond Air's revenue model focuses on selling or leasing its devices to hospitals and clinics, as well as potentially earning royalties or licensing fees from strategic partnerships. Additionally, the company invests in research and development to expand the therapeutic applications of its platform and enhance its market potential.

Beyond Air Earnings Call Summary

Earnings Call Date:Jun 17, 2025
(Q4-2025)
|
% Change Since: -25.00%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call presents a generally positive outlook driven by significant revenue growth, strong future guidance, and successful international expansion. However, financial challenges such as net loss and cost exceedances are areas of concern.
Q4-2025 Updates
Positive Updates
Record-Breaking Revenue Growth
For the fiscal year ended March 31, 2025, Beyond Air reported a 220% increase in revenue to $3.7 million compared with $1.2 million for the same period last year.
Strong Revenue Guidance
The company provided revenue guidance of $12 million to $16 million for the full fiscal year ending March 31, 2026, indicating sustained high growth.
Expansion into International Markets
Beyond Air has expanded its commercial program across Europe, Southeast Asia, and the Middle East, signing distribution agreements in over two dozen countries.
FDA Submission for Next-Generation Device
Beyond Air submitted a PMA supplement for LungFit PH II, a smaller, lighter, and more transportable version of the current FDA-approved system.
Notable Partnerships and Recognition
Beyond Air partnered with Vanderbilt University Medical Center as the first luminary site for LungFit PH and announced the appointment of Bob Goodman to its Board of Directors.
Negative Updates
Net Loss and Gross Profit Challenges
Net loss attributed to common stockholders was $46.6 million for the fiscal year, with a gross profit loss of $1.7 million. Cost of revenue exceeded revenue due to depreciation and upgrade costs.
Operational and Market Challenges
Cost of revenue of $5.4 million exceeded revenue, driven by the depreciation of LungFit devices and onetime upgrade costs. Additionally, geopolitical factors and regulatory processes pose challenges in international markets.
Company Guidance
During the Beyond Air financial results call for the fiscal year ended March 31, 2025, the company reported a 220% increase in revenue to $3.7 million compared to the previous year, driven primarily by U.S. sales. They forecast at least $1.7 million in revenue for the quarter ending June 30, 2025, which represents over a 45% sequential growth and more than 145% year-over-year growth. For the fiscal year ending March 31, 2026, Beyond Air provided revenue guidance of $12 million to $16 million. The company also announced the submission of a PMA supplement to the FDA for their next-generation LungFit PH II device, which is designed for air and ground transportation. Internationally, Beyond Air has signed distribution agreements in over two dozen countries and has begun shipping LungFit PH units outside the U.S. The company reported a net loss of $46.6 million for fiscal 2025, with a cash burn reduction of over 28% from the previous year.

Beyond Air Financial Statement Overview

Summary
Beyond Air is facing significant financial challenges with persistent losses, negative cash flows, and a high debt-to-equity ratio. Despite some revenue growth, the company struggles with profitability and relies heavily on debt financing, indicating potential financial risks.
Income Statement
30
Negative
Beyond Air shows a challenging financial performance with consistent net losses over the years. The gross profit margin and net profit margin are negative, indicating the company is not covering its costs with its revenue. Revenue growth is volatile, with significant increases in 2024 and 2025, yet it remains insufficient to offset operating losses. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.
Balance Sheet
40
Negative
The company has a high debt-to-equity ratio, indicating a reliance on debt financing, which could pose risks if revenue growth does not improve. The equity ratio is weakening, and return on equity is negative due to sustained net losses, reflecting poor returns for shareholders. The balance sheet reveals decreasing stockholders' equity and a decline in cash reserves, suggesting financial strain.
Cash Flow
35
Negative
Operating cash flow is consistently negative, reflecting cash outflows from operations. Free cash flow is also negative, though there is a slight improvement from 2024 to 2025. The operating cash flow to net income ratio remains unfavorable, and the free cash flow to net income ratio indicates the company's ongoing struggle to generate cash from its operations.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue3.71M1.16M0.000.00873.00K
Gross Profit-1.66M-1.31M-555.00K-588.00K873.00K
EBITDA-41.89M-59.03M-58.20M-42.70M-22.02M
Net Income-46.63M-60.24M-55.82M-43.18M-22.88M
Balance Sheet
Total Assets30.06M56.96M68.75M99.20M40.52M
Cash, Cash Equivalents and Short-Term Investments6.92M34.47M45.88M80.24M34.63M
Total Debt11.69M17.84M3.59M3.49M6.93M
Total Liabilities15.72M29.77M26.72M20.99M10.06M
Stockholders Equity13.58M25.05M37.91M72.70M30.46M
Cash Flow
Free Cash Flow-44.10M-61.76M-36.89M-24.58M-20.53M
Operating Cash Flow-38.22M-56.01M-33.01M-23.13M-19.64M
Investing Cash Flow14.90M-12.23M-20.59M-1.45M-890.00K
Financing Cash Flow16.65M43.17M2.70M79.45M30.33M

Beyond Air Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.21
Price Trends
50DMA
0.19
Positive
100DMA
0.23
Negative
200DMA
0.33
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
55.68
Neutral
STOCH
88.91
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XAIR, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.19, and below the 200-day MA of 0.33, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.68 is Neutral, neither overbought nor oversold. The STOCH value of 88.91 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XAIR.

Beyond Air Risk Analysis

Beyond Air disclosed 73 risk factors in its most recent earnings report. Beyond Air reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Beyond Air Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$98.37M12.665.00%0.29%-22.13%
66
Neutral
$75.81M41.773.46%24.75%-61.29%
64
Neutral
¥338.86B10.95-2.99%2.58%11.77%-10.17%
55
Neutral
$195.20M-14.10%5.73%72.50%
46
Neutral
$109.90M-60.68%19.84%5.77%
45
Neutral
$333.48M-30.11%15.32%15.73%
43
Neutral
$19.30M-241.40%219.67%56.69%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XAIR
Beyond Air
0.20
-0.40
-66.67%
FONR
Fonar
15.46
-0.89
-5.44%
INGN
Inogen
7.31
-1.69
-18.78%
SRTS
Sensus Healthcare
4.59
-1.10
-19.33%
NNOX
Nano-X Imaging
5.18
-3.32
-39.06%
LUNG
Pulmonx
2.73
-4.50
-62.24%

Beyond Air Corporate Events

Shareholder MeetingsStock Split
Beyond Air Approves Reverse Stock Split Proposal
Neutral
Jun 25, 2025

On June 20, 2025, Beyond Air, Inc. held a special meeting of stockholders where a reverse stock split proposal was approved. The proposal grants the board of directors the authority to implement a reverse stock split at a ratio between 1-for-10 and 1-for-50 within a year, potentially impacting the company’s stock structure and market perception.

The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Executive/Board ChangesBusiness Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Beyond Air Appoints Robert Goodman to Board
Positive
Jun 18, 2025

On June 16, 2025, Beyond Air appointed Robert Goodman to its Board of Directors, bringing his extensive experience in healthcare leadership to the company. Additionally, Beyond Air announced the submission of a premarket approval supplement to the FDA for its second-generation LungFit PH device, which could significantly enhance its market potential. The company reported a 220% increase in annual revenue for the fiscal year ending March 31, 2025, driven by the demand for LungFit PH and international expansion. Despite a net loss, Beyond Air’s strategic moves, including new distribution partnerships and regulatory approvals, position it for a pivotal year ahead.

The most recent analyst rating on (XAIR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Beyond Air stock, see the XAIR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025